RUA Life Sciences PLC GM Result, Issue of Equity & Total Voting Rights (8682C)
23 Junio 2021 - 6:13AM
UK Regulatory
TIDMRUA
RNS Number : 8682C
RUA Life Sciences PLC
23 June 2021
23 June 2021
RUA Life Sciences plc
(the "Company" or the "Group")
Results of General Meeting
Issue of Equity
and
Total Voting Rights
RUA Life Sciences plc (AIM: RUA), the holding company of a group
of medical device businesses focused on the exploitation of
Elast-Eon(TM) , a long-term implantable biostable polymer, is
pleased to announce that at its General Meeting held earlier today,
all resolutions proposed were duly passed by shareholders.
The Company has resolved to issue the New Ordinary Share to fund
the Buy Back of its Deferred Shares subject only to Admission.
Following Admission, the Company's issued share capital will
comprise 22,184,798 Ordinary Shares, of which none are held in
treasury, and 4,832,778 Deferred Shares which carry no voting
rights. The above figure of 22,184,798 may be used by Shareholders
as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change to their interest in, the voting rights of the Company under
the FCA's Disclosure Guidance and Transparency Rules.
Details of the proxy votes cast on each resolution are set out
below:
Resolution For & Discretionary Against Withheld Total
votes
cast
Number % Number % Number %
of votes of votes of votes
------------ -------- ---------- ----- ---------- -----
Authorising
entry into Buy
Back Agreement
1. (Ordinary Resolution) 6,040,886 100.00 0 0.00 64 0.00 6,040,886
----------------------- ------------ -------- ---------- ----- ---------- ----- ----------
Adopting New
Articles of
Association
2. (Special Resolution) 6,033,636 99.88 7,250 0.12 64 0.00 6,040,886
----------------------- ------------ -------- ---------- ----- ---------- ----- ----------
Unless otherwise defined herein, capitalised terms used in this
announcement shall have the same meanings as defined in the
Circular sent to Shareholders dated 4 June 2021.
For more information please contact:
RUA Life Sciences plc
Bill Brown, Chairman Tel: +44 (0) 77 3071 8296
David Richmond, CEO Tel: +44 (0) 78 9999 6400
Shore Capital (Nomad and Joint Broker)
Tom Griffiths/David Coaten Tel: +44 (0) 20 7408 4080
Cenkos Securities plc (Joint Broker) Tel: +44 (0) 20 7397 8900
Russell Cook/Max Gould (Corporate Finance)
Michael Johnson (Sales)
About RUA Life Sciences
The RUA Life Sciences group was created in April 2020 when RUA
Life Sciences Plc (formerly known as AorTech International Plc)
acquired RUA Medical Devices Limited to create a fully formed
medical device business. RUA Life Sciences is the holding company
of the Group's four trading businesses, each exploiting the Group's
patented polymer technology.
Our vision is to improve the lives of millions of patients by
improving and enabling medical devices with Elast-Eon(TM), a
long-term implantable polyurethane.
Whether it is licensing Elast-Eon(TM), manufacturing a device or
component or developing next generation medical devices, a RUA Life
Sciences business is pursuing our vision.
Elast-Eon(TM)'s biostability is comparable to silicone while
exhibiting excellent mechanical, blood contacting and flex-fatigue
properties. These polymers can be processed using conventional
thermoplastic extrusion and moulding techniques. With over 7
million implants and over 14 years of successful clinical use,
RUA's polymers are proven in long-term life enabling
applications.
The Group's four business units are:
RUA Medical : End-to-end contract designer and manufacturer
of medical devices and implantable fabric specialist.
RUA Biomaterials: Licensor of Elast-Eon(TM) polymers to the medical
device industry.
RUA Vascular: Commercialisation of large bore polymer sealed
grafts and soft tissue patches.
RUA Structural Development of polymeric leaflet systems for
Heart: heart valves.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFXLFLFQLBBBK
(END) Dow Jones Newswires
June 23, 2021 07:13 ET (11:13 GMT)
Aortech (LSE:AOR)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Aortech (LSE:AOR)
Gráfica de Acción Histórica
De May 2023 a May 2024